Abstract 12494: Association of Plasma n-3 Polyunsaturated Acids Levels with Metabolic and Inflammatory Biomarkers in Patients With Chronic Heart Failure. Data from the GISSI-HF Trial
Aims: Inverse associations between circulating n-3 polyunsaturated acids (n-3 PUFA) levels and inflammatory biomarkers have been reported in subjects with cardiovascular risk factors or with coronary artery disease. We assessed here their relation to metabolic, inflammatory, and cardiac markers in a large cohort of patients with stable chronic heart failure (HF).
Methods: Plasma levels of n-3 PUFA (% of total fatty acids in phospholipids, assayed by gas chromatography) and metabolic (adiponectin), inflammatory (C-reactive protein (hsCRP), pentraxin-3 (PTX3), osteoprotegerin (OPG)), or cardiac biomarkers (natriuretic peptide (NT-proBNP), troponin T (hs-cTnT)) were measured at baseline in 1,203 patients with CHF of any etiology and age enrolled in the GISSI-HF trial.
Results: Patients with n-3 PUFA levels in the upper third (>5.4%) had more frequently HF of ischemic etiology, lower SBP, milder symptoms of HF (NYHA class II), less often COPD. Levels of n-3 PUFA were inversely related to adiponectin (Spearman r=-0.13, p<0.0001, Figure) and PTX3 (r=-0.09, p=0.0015); the associations with other biomarkers were weaker. In multivariable linear regression models adjusted for anthropometric and clinical variables, n-3 PUFA levels were inversely associated with adiponectin (β(SE)= -0.030(0.007), p=0.0001), PTX3 (−0.022(0.011), p=0.03) or hsCRP (−0.038(0.018), p=0.04).
Conclusions: We show in patients with HF an original association between plasma levels of n-3 PUFA and a marker of insulin resistance/poor outcome in HF (adiponectin) or inflammatory pentraxins (PTX3, CRP). These mechanisms may help to explain some of the benefits of n-3 PUFA in cardiovascular diseases.
- © 2010 by American Heart Association, Inc.